Relmada Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/B Ratio0.441.460.753.004.93
Price/Tangible Book0.441.460.753.004.93
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)-1.32%-0.88%-0.90%-0.80%-0.54%
Return on Assets (ROA)-0.73%-0.52%-0.54%-0.46%-0.32%
Return on Capital Employed (ROCE)-2.36%-1.22%-1.15%-0.60%-0.56%
Leverage & Solvency Ratios
Liquidity Ratios
Current Ratio4.458.0012.2614.839.37
Quick Ratio4.367.9011.9414.089.30
Efficiency Ratios
Yield & Distribution Ratios
Earnings Yield-5.10%-0.79%-1.50%-0.20%-0.11%
FCF Yield-3.30%-0.41%-0.99%-0.15%-0.05%
Buyback Yield0.00%-0.02%-0.69%-0.13%-0.69%